Betatrophin Levels Research Articles

Circulating betatrophin/ANGPTL8 levels correlate with body fat distribution in individuals with normal glucose tolerance but not those with glucose disorders

BackgroundThe relationship between betatrophin/ANGPTL8 and obesity has been investigated using body mass index (BMI); however, since BMI reflects overall adiposity rather than body fat distribution, it remains unclear whether fat deposition in different areas of the body affects betatrophin expression. Here, we investigated the correlation between circulating betatrophin levels and body fat distribution in patients with different glucose tolerance.MethodsWe performed a cross-sectional study in 128 participants with impaired glucose tolerance (IGT; n = 64) or normal glucose tolerance (NGT; n = 64). Circulating betatrophin levels were detected by enzyme-linked immunosorbent assay (ELISA). Body fat distribution (subcutaneous, visceral, and limb fat) was measured by magnetic resonance imaging (MRI) and a body fat meter.ResultsAfter controlling for age, sex, and BMI, betatrophin was correlated positively with visceral adipose tissue-to-subcutaneous adipose tissue ratio (VAT/SAT ratio; r = 0.339, p = 0.009) and negatively with body fat ratio (BFR; r = − 0.275, p = 0.035), left lower limb fat ratio (LLR; r = − 0.330, p = 0.011), and right lower limb fat ratio (RLR; r = − 0.288, p = 0.027) in the NGT group, with these correlations remaining after controlling for triglycerides. VAT/SAT ratio (standardized β = 0.419, p = 0.001) was independently associated with serum betatrophin levels; however, betatrophin was not associated with body fat distribution variables in the IGT group.ConclusionsCirculating betatrophin levels correlated positively with VAT/SAT ratio and negatively with lower limb fat, but not with subcutaneous or upper limb fat, in individuals with normal glucose tolerance. Thus, betatrophin may be a potential biomarker for body fat distribution in individuals without glucose disorders.

The Effects of Continuous and High Intensity Interval Trainings on Plasma Betatrophin Level in Diabetic Rats Treated with Metformin

Objective: The study aimed to determine the effect of eight weeks high intensity interval (HIIT) and sub-maximal continuous trainings on plasma betatrophin level in diabetic rats treated with metformin. Materials and Methods: In this experimental study, 42 diabeticwistar rats were divided into six groups (n=7): diabetic control (C), diabetic control + metformin consumption(C+M), diabetic HIIT, diabetic HIIT + metformin (HIIT+M), diabetic sub-maximal continuous training (SMCT), and diabetic sub-maximal continuous training + metformin (SMCT+M). Metformin was given 150 mg/kg/day by gavage every day, 48 hours after the end of the last training session, the rats were sacrificed. Then blood glucose and glycated hemoglobin (HbA1c) levels were measured. One-way ANOVA test was used for statistical analysis of data. Results: The level of plasma betatrophin was significantly different in the HIIT ( P -value= 0.01) and C+M ( P -value= 0.001) groups compared to C group. Blood glucose was significantly decreased in all training groups with or without betatrophin compared with the diabetic control group ( P -value= 0.001). However, there were no significant changes between glucose levels in HIIT, HIIT+M, SMCT, and SMCT+M groups but SMCT showed most reduction in blood glucose. Conclusion: Treatment with metformin did not change blood glucose but two types of exercise training with high and moderate intensity reduced blood glucose thus exercise can be a good alternative modality rather than taking medicine.

Evaluation of second-trimester maternal serum betatrophin levels and lipid and carbohydrate metabolism parameters in patients with gestational diabetes mellitus.

Objective:We investigated the role of betatrophin in the etiopathogenesis of gestational diabetes mellitus (GDM) and its association with lipid and carbohydrate metabolism in patients with GDM and normoglycemic pregnant women.Materials and Methods:A total of 60 patients [30 pregnant women with GDM (study group) and 30 healthy age-, body mass index-, and gestational agematched pregnant women (control group)] were included in this study. Serum betatrophin, fasting glucose, insulin, glycated hemoglobin A1c (HbA1c), and C-peptide levels, as well as lipid parameters, were measured.Results:Serum betatrophin, fasting glucose, HbA1c, insulin, and C-peptide levels were significantly higher in the GDM group than in the control group (p<0.001, p=0.009, p=0.013, p<0.001, and p<0.001, respectively). Levels of triglycerides and very-low-density lipoprotein cholesterol were significantly higher in the GDM group (p=0.020 and p=0.020, respectively), but total cholesterol and LDL cholesterol levels were similar in the two groups (p=0.810 and p=0.273, respectively). Betatrophin levels in the GDM group were correlated positively with insulin levels (r=0.336, p=0.009) and the homeostatic model assessment of insulin resistance (HOMA-IR) score (r=0.269, p=0.038), and negatively with the C-peptide levels (r=-0.399, p=0.002); they were not correlated with any other glucose or lipid parameters. Multivariate stepwise linear regression analysis demonstrated that insulin levels (β=0.134, p=0.013) and the HOMA-IR score (β=0.112, p=0.017) were associated independently with serum betatrophin levels.Conclusion:These results demonstrate that serum betatrophin levels were significantly higher in pregnant women with GDM than in normoglycemic pregnant women. The levels of betatrophin were correlated significantly with insulin resistance parameters, which is a key feature of GDM pathophysiology.

Serum betatrophin levels are significantly increased in obese patients compared to lean patients regardless to the presence of PCOS

Betatrophin, which regulates glucose metabolism, is primarily expressed in liver and fat tissue. We aimed to investigate betatrophin levels in patients with polycystic ovary syndrome (PCOS) that is the most common endocrine pathology in women of reproductive age. A total of 69 women were included in this prospective study: 35 patients with PCOS (18 obese and 17 lean) and 34 healthy controls (17 obese and 17 lean). Patients who met the criteria were compared regarding betatrophin levels and other hormonal values. Serum betatrophin level did not differ between obese PCOS patients and obese controls, and lean PCOS patients and lean controls; while significantly increased in obese PCOS patients and controls compared to lean PCOS patients and controls. Total testosterone and androstenedione were significantly higher in patients with PCOS than in controls both in the obese and lean groups, while sex hormone–binding globulin was significantly lower in patients with PCOS than in controls both in the obese and lean groups. However, remaining hormone values were similar between groups. Betatrophin level was significantly increased in obese patients compared to lean patients independent to the presence of PCOS.

A Potential Pathological Role of Wingless Type1 Inducible Signaling Pathway Protein-1 and Betatrophin in Obese Women with Polyststic Ovary Syndrome

Background: Polycystic Ovary Syndrome is a common female endocrinopathy. It is associated with adipokines dysfunctional secretion pattern and insulin resistance, which is considered as the main reason for its clinical feature. Wingless type1 inducible signaling pathway protein-1 is a novel adipokine that displays insulin resistance and adipose tissue inflammation where it strongly related to adipocyte accumulation and regeneration. Betatrophin has a potential role in pancreatic beta-cell proliferation and obesity and several studies showed inconsistent betatrophin levels in patients with diabetes and obesity but, its relation to polycystic ovary syndrome is unclear.&#x0D; Aim: Investigation of the role of serum wingless type1 inducible signaling pathway protein-1 and betatrophin in normal weight and obese patients with polycystic ovary syndrome. Studying their association with other markers, then determine whether obesity and insulin resistance is associated with them.&#x0D; Methods: Wingless type1 inducible signaling pathway protein-1 and betatrophin serum levels were measured in 44 patients with polycystic ovary syndrome (22 obese and 22 non-obese) and 44 matched control (22 obese and 22 non-obese) females using specific ELISA kits. &#x0D; Results: Betatrophin and wingless type1 inducible signaling pathway protein-1 levels were elevated in the polycystic ovary syndrome group (49.4 pg/ml, 187.6 pg/ml) than in the control group (32.08 pg/ml, 108.4 pg/ml) respectively. Moreover, their levels were higher in the obese subgroup than in normal weight subgroup. There were positive correlations between wingless type1 inducible signaling pathway protein-1 and betatrophin in non-obese (r=0.89, p=0.0001***) and in obese (r=0.78, p=0.0001***) polycystic ovary syndrome groups.&#x0D; Conclusion: Betatrophin and wingless type1 inducible signaling pathway protein-1 are associated with adiposity and insulin resistance in polycystic ovary syndrome. Hence wingless type1 inducible signaling pathway protein-1 and betatrophin may play a role in the incidence of polycystic ovary syndrome. They may be valuable in diagnosis and prediction of polycystic ovary syndrome patients.

Association of serum sestrin 2 and betatrophin with serum neutrophil gelatinase associated lipocalin levels in type 2 diabetic patients with diabetic nephropathy

PurposeUnderstanding the pathogenesis and the molecular mechanisms of diabetic nephropathy (DN) helps its timely detection and prevention. The current work aims tomeasure serum sestrin 2 and betatrophin levels in healthy and type diabetic (T2DM)subjects with/or without diabetic nephropathy (DN) and also to test their correlation with serum neutrophil gelatinase associated lipocalin (sNGAL); indicator of DN.MethodsThis study included 96 subjects; 20 healthy (G1) and 76 T2DM [22 normoalbuminuric (G2), 35 microalbuminuric (G3) and 19 macroalbuminuric (G4)]. Serum sestrin 2, betatrophin and NGAL were measured by their corresponding kits.ResultsSignificant low levels of serum sestrin 2 andhigh levels of serum betatrophin were found in T2DM group when compared to G1 (p = 0.002,p > 0.001, respectively) and this difference is manifested in G4 followed, in order, by G3, G2 then G1 (p= > 0.001 for both). Also, serum sestrin2 levels showed significant negative correlations with sNGAL in G1 (r = −0.497, p = 0.026), G2 (r = −0.784, p > 0.001), G3 (r = −0.894, p > 0.001) and G4 (r = −0.896, pp. > 0.001) while serum betatrophin levels showed significant positive correlations with sNGAL in G2 (r = 0.681, p > 0.001), G3 (r = 0.518, p > 0.001) and G4 (r = 0.727, p > 0.001).ConclusionSerum sestrin 2 levels decrease significantly while betatrophin levels increase significantly in T2DM patients with DN especially those with macroalbuminuria. These levels have significant effect strengths on the indicator of diabetic nephropathy; sNGAL which might indicate theirvaluablerole in the timely detection and prevention of the development of DN.

Adipose Insulin Resistance and Circulating Betatrophin Levels in Women with PCOS.

The role of IR and metabolic disorders has become a crucial topic of study in the pathogenesis of PCOS. Adipose tissue is an important target organ of insulin, and adipose IR plays an important role in the occurrence and development of PCOS. This study seeks to investigate the role of adipose IR in the development of PCOS and to examine its relationship with circulating betatrophin levels in women with PCOS. A cross-sectional analysis of a cohort of women with PCOS and healthy women was performed in this study. Serum betatrophin concentrations were measured by ELISA. Adipose IR was calculated using the product of fasting insulin and FFA concentrations, and the relationship between adipose IR, circulating betatrophin, and other parameters was analyzed. Adipose IR in women with PCOS was significantly higher than that in controls. We found that women with PCOS who have adipose IR (adipose IR ≥ 55) have a higher BMI and higher blood glucose, insulin, PRL, FFA, TG, HOMA-IR, AUCglucose, AUCinsulin, VAIfemale, and BAI levels than PCOS-afflicted women without adipose IR, while M-values, and SHBG and LH levels were lower. In women with PCOS, serum betatrophin levels were significantly increased compared with controls. Adipose IR negatively correlated with M values and positively with circulating betatrophin levels in the study population. After metformin treatment, circulating betatrophin levels and adipose IR in women with PCOS were significantly decreased compared with pretreatment. Adipose IR is associated with betatrophin levels in women with PCOS. The combination of adipose IR and circulating betatrophin measurements may be significant for screening patients with PCOS.

Association of Betatrophin, TNF- and #945; and IL-6 with diabetic microvascular and macrovascular complications

Aim: The most important goal in the treatment of Diabetes Mellitus is to protect patients from micro and macro complications. Inflammatory cytokines and betatrophin have been reported to play a role in diabetic micro and macro complications. This study aimed to investigate the effect of serum Betatrophin, TNF-α and IL-6 levels on diabetic micro and macro complications in patients with type 2 Diabetes Mellitus. Materials and Methods: This case-control study was conducted with 91 type 2 Diabetes Mellitus (T2DM) patients between January-December 2018. Case series with 91 patients divided into three groups were included; 31 T2DM patients without diabetic complications (group 1=control), 30 patients with diabetic microvascular complications (group 2) and 30 patients with diabetic macrovasculer complications (group 3). Blood was collected to evaluate biochemical parameters, TNF-α, IL-6 and betatrophin. Results: Betatrophin level was high in patients with renitopathy (p=0.042) and diabetic foot (p=0.036). TNF-α levels were higher in patients with both microvascular and macrovascular complications compared to the control group (p

Effects of vitamin D on apoptosis and betatrophin in the kidney tissue of experimental diabetic rats.

The aim of this study is to investigate the effects of vitamin D on betatrophin and apoptosis in rats kidney tissue using an experimental diabetes model created with streptozotocin (STZ). 41 male Wistar-albino breed rats were assigned to 5 groups, which included 3 groups consisting of 7 animals each and 2 groups consisting of 10 animals each. The control group received no treatments. Single-dose 0.1 M sodium buffer was administered ip to the Buffer group. The Vitamin D group was orally administered 200 IU/day vitamin D. The Diabetes group was injected ip with single-dose 50 mg/kg STZ by dissolving the material in 0.1 M sodium buffer. Subjects with a glucose level exceeding 250 mg/dl were accepted to be diabetic. The Diabetes + Vitamin D group was injected ip with 50 mg/kg single-dose STZ by dissolving the material in 0.1 M sodium buffer. Once diabetes was established, 200 IU/day vitamin D was administered orally. Rats in all groups were decapitated in the end of the experiment, their kidney tissues were promptly extracted and TUNEL stained with immunohistochemistry. Additionally, serum samples acquired from all groups were evaluated with regard to total antioxidant status (TAS) and total oxidant status (TOS) levels. The histological and biochemical analyses of the Control, Buffer, and Vitamin D groups revealed similar serum TOS and TAS levels, and TUNEL positivity and betatrophin immunoreactivity. While the Diabetes group showed significantly higher TOS levels and TUNEL positivity compared to the Control group, their TAS levels and betatrophin immunoreactivity were significantly reduced. The Diabetes+Vitamin group demonstrated significantly lower TOS levels and TUNEL positivity compared to the Diabetic group, and their TAS levels and betatrophin immunoreactivity increased significantly. In conclusion; experimental diabetes was found to increase TOS and apoptotic cells and decrease TAS and betatrophin levels in kidney tissue in experimental diabetes, and that administering VitD as treatment caused a decrease in TOS and apoptotic cells and an increase in TAS and betatrophin levels. It was concluded that future studies needed to investigate various experimental diabetes times so that the role of diabetes in the pathophysiology of its effect on kidney tissue could be uncovered. (www.actabiomedica.it)

The relationship between betatrophin levels and HbA1c: A case control study

The relationship between betatrophin levels and HbA1c: A case control study

RUTIN RESTORE BIOCHEMICAL CHANGES, OXIDATIVE STRESS AND BETATROPHIN LEVEL IN STZ-INDUCED DIABETIC RATS

Objective: Diabetes mellitus (DM) is associated with long-term damage, dysfunction, of various organs. Study aims to assessrole of rutin on experimentally induced diabetes.&#x0D; Methods: 50 adult male albino rats divided into 5 groups. Group I (control group, rats were orally administered with 1 ml saline daily). Group II (DMSO group, rats were orally administered with 0.2 % DMSO for 60 d orally). Group III (positive control, animals were injected intraperitoneally with 60 mg/kg b. wtstreptozotocin followed by intraperitoneal injection with 120 mg/kg b. wt of Nicotinamide after 15 min). Group IV (therapeutic group, diabetic rats treated with 100 mg/kg b. wt of rutin for 60 d orally). Group V (standard group, diabetic animals treated with 100 mg/kg b. wt of metformin for 60 d orally). At the end of the experimental period blood serum and plasma, liver, kidney and pancreatic tissues were collected.&#x0D; Results: Diabetic rats showed a significant increase in plasma glucose, serum urea, creatinine, cholesterol and triglyceride. Also, induced oxidative stress as pointed out an increase in MDA level, decrease in GSH level, GST and CAT activities in compared to control group. Also, showed an increase in plasma and tissues levels of betatrophin. Oral administration of rutin cause decrease in elevated biochemical and oxidative stress parameters. Also, decrease betatrophin level when compared with diabetic rats. Our results were confirmed by histopathological examination of different tissues.&#x0D; Conclusion: This study suggests thatrutinexihibitsantihyperglycemic and antioxidant activity in streptozotocin-induced diabetic rats.

Several Circulating Biomarkers for PCOS Diagnosis.

Irisin, Betatrophin and Zinc-α2-glycoprotein (ZAG) have been shown to be associated with insulin resistance (IR) and polycystic ovary syndrome (PCOS), respectively. The purpose of this study is to explore the potential accuracy of this combination of three cytokines in screening PCOS. 186 individuals were recruited for this study. Circulating Irisin, Betatrophin and ZAG concentrations were measured by enzyme-linked immunosorbent assay. The association between these serum biomarkers and PCOS was assessed by logistic regression analysis. Receiver operating curve (ROC) analysis was performed to evaluate the diagnostic value of these biomarkers for PCOS women. In women with PCOS, serum Irisin and Betatrophin levels were markedly elevated compared to those in healthy controls (p<0.01), while ZAG levels were lower (p<0.01). PCOS women with IR (M-value<6.28) had lower circulating ZAG concentrations, and higher circulating Irisin and Betatrophin levels relative to PCOS women without IR (M-value ≥ 6.28). ROC curve analyses showed that the AUC for Irisin, ZAG and Betatrophin for predicting PCOS were 0.77, 0.83 and 0.85, respectively. In a joint ROC curves analysis of these serum markers and other parameters, the results showed that the AUC was 0.93, and the sensitivity and specificity were 82.1 % and 92.3 %, respectively. When compared to using single cytokine, the analysis of Irisin, ZAG and Betatrophin elevates the accuracy in diagnosing PCOS.

The Relationship between Circulating ANGPTL8/Betatrophin Concentrations and Adult Obesity: A Meta-Analysis.

In this study, we evaluated the relationship between circulating betatrophin levels and obesity. Obesity is a common public health problem that is increasing globally. Betatrophin, a newly identified protein, is predominantly expressed in white and brown fat tissues and in the liver. Growing evidence suggests that betatrophin plays a pivotal role in metabolism, including the synthesis and degradation of lipids in cells, and adipocyte differentiation. Previous studies have assessed the association between circulating betatrophin levels and obesity; however, this relationship remains unclear. Therefore, our study is aimed at examining the impact of betatrophin on obesity using a meta-analysis of the current evidence. We performed a meta-analysis to quantify the relationship between betatrophin levels and obesity. A literature search was conducted through the EMBASE, Web of Science, and MEDLINE databases. Retrieved studies were screened, without any language restrictions to identify relevant literature published up to December 2018. Observational studies, in which the association between circulating concentrations of betatrophin and obesity was evaluated, were considered suitable for the systematic review. Of the 65 manuscripts retrieved, 9 datasets from 6 studies, involving 681 participants, detected an association between circulating betatrophin and obesity. Circulating betatrophin levels of obese subjects were higher than those of nonobese subjects (random − effects weighted mean difference (WMD) = 0.250 μg/mL, 95% CI: 0.048–0.451, I2 = 94.8%, p = 0.015), yet with significant between-study heterogeneity. This heterogeneity appeared to be modified by glycemic status but not by age, the ELISA kits used, sample source, or body mass index. The high circulating betatrophin concentration may directly increase the risk of obesity in adults. Betatrophin may serve as a therapeutic target for obesity in adults.

Plasma Betatrophin Levels and Carotid Atherosclerosis.

Aims Betatrophin is a recently identified circulating adipokine that may affect lipid and glucose metabolism. However, the association between plasma betatrophin levels and carotid atherosclerosis has not been elucidated. Methods We investigated plasma betatrophin levels in 153 subjects undergoing carotid ultrasonography. The severity of plaque was evaluated as plaque score. Results Of the 153 subjects, plaque was found in 63 (41%). Plasma betatrophin levels were higher in 63 subjects with plaque than in 90 without plaque (median 906 vs. 729 pg/mL, P < 0.025). A stepwise increase in betatrophin levels was found depending on the plaque score: 729 pg/mL in score = 0 (n = 90), 802 pg/mL in score = 1 (n = 31), and 978 pg/mL in score ≥ 2 (n = 32) (P < 0.01). In particular, betatrophin levels in subjects with score ≥ 2 were higher than in those with score = 0 (P < 0.05). Moreover, betatrophin levels correlated with plaque score (r = 0.23, P < 0.01), but no significant correlation was found between betatrophin levels and triglyceride or HbA1c levels. The percentage of subjects with betatrophin > 800 pg/mL was higher in subjects with plaque than in those without plaque (65% vs. 44%) and was highest in score ≥ 2 (78%) (P < 0.005). In the multivariate analysis, betatrophin level was not a significant factor for the presence of plaque but was a significant factor for plaque score ≥ 2, independent of atherosclerotic risk factors. The odds ratio for score ≥ 2 was 4.9 (95% CI = 1.9-12.8) for betatrophin > 800 pg/mL. Conclusions Plasma betatrophin levels were found to be high in subjects with carotid plaque and to be associated with the severity of plaque. Betatrophin may play a role in the progression of carotid atherosclerosis.

The effects of overt hypothyroidism on adipose tissue and serum betatrophin levels

Aim: Betatrophin, also known as angiopoietin-like peptide-8, is an adipokine in glycoprotein structure synthesized from adipose tissue and liver. Betatrophin plays a role in fat and energy metabolism by inhibiting lipoprotein lipase, the key enzyme in the hydrolysis of plasma lipoproteins. Although thyroid hormones have an active role in energy metabolism, their relationship with cholesterol and lipid metabolism is not clear. In our study, we aimed to investigate the relationship of serum betatrophin levels with energy and lipid metabolism in patients with overt hypothyroidism.Methods: This is a case-control study. The mean age of 44 patients (20 males, 24 females) with hypothyroidism was 44.7 (13.8). A total of 40 healthy volunteers, including 19 males and 21 females, were included in the study as a control group. The mean age of healthy volunteers was 44.6 (14.4) years. Fasting blood glucose, AST, ALT, urea, creatinine, TSH, free T3, free T4, HDL-cholesterol, LDL-cholesterol, triglyceride (TG), total cholesterol, anti-TPO, anti-TG, insulin, HOMA-IR levels and serum betatrophin levels were measured by ELISA and compared in both groups.Results: Serum betatrophin levels were significantly higher in patients diagnosed with hypothyroidism compared to the control group (P=0.001). Serum betatrophin levels were positively correlated with TSH, TG and total cholesterol, and negatively correlated with HDL, free T3 and free T4 levels. There was no significant difference in the comparison of patients regarding anti-TPO levels in the hypothyroidism group (P=0.78).Conclusion: In our study, we found that serum betatrophin levels were high in hypothyroid patients. This study may be useful in the development of treatments targeting betatrophin in clinical practice.

Association of serum angiopoietin-like protein 2 with elevated risk of cardiovascular diseases in subjects with type 2 diabetes

AimsAlthough previous data have suggested ANGPTL2 and ANGPTL8 (betatrophin) to be related to atherosclerosis in humans, little is known whether this applies in patients with type 2 diabetes (T2D). In this work, we investigate association of serum ANGPTL2 and betatrophin with the risk of cardiovascular diseases (CVD) in T2D patients. MethodsWe measured serum levels of ANGPTL2 and betatrophin in 150 T2D patients with and without CVD and in 100 control subjects. ResultsSerum ANGPTL2 was significantly higher in T2D patients than in controls (p < 0.0001), and in T2D + CVD patients than T2D only patients (p = 0.0002). Serum betatrophin was lower in T2D patients than in controls but with no statistical significance (p = 0.07). Elevated serum ANGPTL2 associated with 2.83-fold increased risk of T2D and with 1.18-fold elevated risk of CVD among T2D patients with positive correlations with markers of hyperglycemia, insulin resistance and atherogenic lipid profile. ROC curve indicated ANGPTL2 as risk biomarker for T2D and CVD with sensitivity of 92.2% and 86%; and specificity of 86.7% and 58%; respectively. ConclusionWe indicate for the first time serum ANGPTL2 as an independent risk biomarker for CVD in T2D patients. Future studies are needed to reveal its role in disease pathogenesis.

A Study of Serum Betatrophin levels in Children with Type 1 Diabetes Mellitus

A Study of Serum Betatrophin levels in Children with Type 1 Diabetes Mellitus

Comparison of the Effects of Two Different Intensities of Combined Training on Irisin, Betatrophin, and Insulin Levels in Women with Type 2 Diabetes

Background: Betatrophin is a β-cell proliferation marker produced as a result of irisin expression. It is regarded as a therapeutic indicator of diabetes due to elevated insulin secretion. Objectives: The purpose of this study was to compare the effects of 2 different intensities of combined training on the levels of irisin, betatrophin, and insulin in women with type 2 diabetes. Methods: In this study, 26 female patients with type 2 diabetes were divided into 3 groups of combined high-intensity training, combined moderate-intensity training, and control. The training groups participated in combined training at high or moderate intensities for 8 weeks. The variance analysis test and the Duncan post-hoc test were applied to analyze the data (P > 0.05). Results: Combined training at 2 intensities of moderate and vigorous led to a rise in the levels of irisin, betatrophin, and insulin. Exercise intensity was a determining factor for these elevated levels insofar as combined high-intensity training resulted in higher levels of these hormones than combined moderate-intensity training. Conclusions: It appears that participating in relatively high-intensity training programs may be beneficial for diabetic patients inasmuch as they increase the levels of irisin, betatrophin, and then, insulin.

Study of Serum Betatrophin Level as A Novel Endocrinal Regulator Involved in Diabetic Nephropathy Development

AbstractBackground: Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction and failure of various organs. Diabetic Nephrop-athy (DN) is the leading cause of chronic kidney disease which ultimately progresses to end stage renal disease. There-fore, early diagnostic markers for predicting and monitoring the progression of DN are needed to enable the timely admin-istration of the mostly appropriate protective treatments, we hypothesized that betatrophin may be a novel endocrine regulator involved in DN development.Aim of Study: It was to examine circulating betatrophin level in patients with type 2 diabetes mellitus with or without diabetic nephropathy in comparison with healthy controls.Patients and Methods: The study was carried out on forty patients with type 2 diabetes mellitus. They were recruited from internal Medicine Department of Tanta University Hos-pital who classified into, 20 type 2 diabetic patients without nephropathy. 20 type 2 diabetic patients with nephropathy. Another twenty apparently healthy subjects were chosen from outpatient clinics of Tanta University Hospital and served as control group. This study was carried out from June 2016 to May 2017. An approval by Ethical Committee of Tanta Uni-versity Faculty of Medicine was obtained. They were subjected to thorough history taking, clinical examination including anthropometric measurements (sex, age, BMI) and laboratory investigations including glycated Hb, fasting and post prandial blood glucose, liver function tests, UACR, kidney function, lipid profile, serum betatrophin estimation by ELISA.Results: Betatrophin was significantly higher in both T2DM with nephropathy and T2DM as compared to control group and significantly higher in T2DM with nephropathy than T2DM. There was significant positive correlation between betatrophin hormone and HbA1c, BMI, serum total cholesterol, serum triglycerides, LDL and negative correlation with HDL in both T2DM group and T2DM with nephropathy group. There was positive correlation between betatrophin and Albumin/Creatinine Ratio (ACR) in T2DM with nephropathy group. Conclusion: There was no significant correlation between betatrophin and Albumin/Creatinine Ratio (ACR) in T2DM group, while there was positive correlation between betatrophin and ACR in diabetic nephropathy group. Thus, betatrophin may be a novel endocrinal regulator involved in diabetic nephropathy development.

Adipokines at the crossroad between obesity and type 2 diabetes mellitus

Objective: Investigate serum levels of chemerin, apelin, betatrophin and leptin adipokines and HsCRP in obese and non-obese patients either prediabetic or diabetic and correlate their levels with other biochemical parameters of IR. Additionally, studying the effect of their combinations on the sensitivity of investigation for the development and/or progression of T2DM. Subjects: serum levels of adipokines were analyzed using ELISA technique in 160 subjects. Results: Serum Chemerin, Apelin and HsCRP levels were significantly higher in all obese groups compared to non-obese of the same group.Serum levels of both betatrophin & HsCRP were positively correlated with glycemic indices (FPG, A1c, HOMA-IR). Serum levels of chemerin were positively correlated with FPG, A1c. Serum Chemerin, betatrophin, HsCRP all showed negative correlation with HOMA-? level. The combination of different markers improved their sensitivity of detection, with the highest level of sensitivity shown between betatrophin with HsCRP. Conclusion: these results indicate crucial roles played by the studied adipokines and HsCRP in IR caused by obesity and consequently T2DM development. Combination of Betatrophin and HsCRP can be an early sensitive predictor for IR occurrence in obese patients. These adipokines may be targets for the development of therapies to treat or inhibit IR associated to obesity. Keywords: Obesity, Insulin resistance, T2DM, Adipokines, Combined sensitivity.